LOTUSEYE Stock Overview
A specialty eye care hospital, provides eye care and related services in India.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Lotus Eye Hospital and Institute Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹74.64 |
| 52 Week High | ₹111.00 |
| 52 Week Low | ₹48.50 |
| Beta | 0.22 |
| 11 Month Change | 13.18% |
| 3 Month Change | 35.46% |
| 1 Year Change | -16.23% |
| 33 Year Change | 69.25% |
| 5 Year Change | 264.10% |
| Change since IPO | 109.37% |
Recent News & Updates
Recent updates
Optimistic Investors Push Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) Shares Up 25% But Growth Is Lacking
Aug 21
Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings
Jan 24Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50
Sep 08We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease
Jul 15Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors
Apr 07We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease
Oct 08Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50
Sep 02If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity
Jun 17MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)
Mar 11Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)
Dec 30Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares
Nov 20The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares
Sep 21Why Investors Shouldn't Be Surprised By Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) P/E
Aug 27
Should You Take Comfort From Insider Transactions At Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)?
Aug 03Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) P/E Isn't Throwing Up Surprises
Jul 06Shareholder Returns
| LOTUSEYE | IN Healthcare | IN Market | |
|---|---|---|---|
| 7D | -2.9% | 1.5% | 1.0% |
| 1Y | -16.2% | 45.6% | 44.7% |
Return vs Industry: LOTUSEYE underperformed the Indian Healthcare industry which returned 45.6% over the past year.
Return vs Market: LOTUSEYE underperformed the Indian Market which returned 44.7% over the past year.
Price Volatility
| LOTUSEYE volatility | |
|---|---|
| LOTUSEYE Average Weekly Movement | 8.8% |
| Healthcare Industry Average Movement | 5.9% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 9.8% |
| 10% least volatile stocks in IN Market | 4.4% |
Stable Share Price: LOTUSEYE's share price has been volatile over the past 3 months.
Volatility Over Time: LOTUSEYE's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 336 | Kuttapalayam Ramalingam | www.lotuseye.org |
Lotus Eye Hospital and Institute Limited, a specialty eye care hospital, provides eye care and related services in India. The company offers ReLEx SMILE lasik, touch free laser, lasik eye surgery, epilasik, intralase, supracor, robotic femto laser cataract surgery, phacoemulsification, paediatric eye care and squint surgery, and micro incision cataract surgery treatments. It also provides epizyoptix, special kertometer, and synaptophore; SICS, Phaco, MICS, LRCS, SFLOL, and SF IOL cataract surgery; corneal patchgraft, scleral repair, scrapping + AMG, suture, tatooing, tear suturing, and drop removal; pertygium, C3R, penetrating keratoplasty, TPK and DALK, and DASE; membrane peeling and endolaser; ERM removal, silicon oil and removal, vitrectomy lavage, FGE and C3F8, LPFC and CYCLO CRYO, and scleral buckling and belt buckle; ivta, avastin, razumab, ozurdex, zybev, eyelea, lucentis, and accentrix injections; trabeculectomy; and enucleation, evisceration, DCR and DCT, PTOSIS, and lateral tarsorrhaphy services.
Lotus Eye Hospital and Institute Limited Fundamentals Summary
| LOTUSEYE fundamental statistics | |
|---|---|
| Market cap | ₹1.55b |
| Earnings (TTM) | ₹21.54m |
| Revenue (TTM) | ₹485.33m |
72.1x
P/E Ratio3.2x
P/S RatioIs LOTUSEYE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LOTUSEYE income statement (TTM) | |
|---|---|
| Revenue | ₹485.33m |
| Cost of Revenue | ₹354.74m |
| Gross Profit | ₹130.60m |
| Other Expenses | ₹109.06m |
| Earnings | ₹21.54m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.04 |
| Gross Margin | 26.91% |
| Net Profit Margin | 4.44% |
| Debt/Equity Ratio | 1.9% |
How did LOTUSEYE perform over the long term?
See historical performance and comparison